Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Average Reviews

Description

Company Challenge:

Last August, Cambridge, Massachusetts–based Alnylam Pharmaceuticals became the first company to bring an RNA interference (RNAi) treatment to market, winning FDA approval for its drug Onpattro. The drug treats peripheral nerve damage and other symptoms in people with the rare and previously untreatable condition of hereditary amyloidosis.

Volunteers

Bootcamp

Internship

Categories

Statistic

32 Views
0 Rating
0 Favorite
Share

Map

Claim Listing

Is this your business?

Claim listing is the best way to manage and protect your business.